Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice

Eriko Inoue, Toshihiro Ichiki, Kotaro Takeda, Hirohide Matsuura, Toru Hashimoto, Jiro Ikeda, Aya Kamiharaguchi, Kenji Sunagawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Obesity induces hypertrophy of adipocyte resulting in production of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-α) and monocyte chemoattractant protein 1 (MCP1 (CCL2)). These cytokines play an important role in the development of insulin resistance. Beraprost sodium (BPS), a prostaglandin I2 analogue, is reported to attenuate inflammation. In this study, we examined the effect of BPS on glucose metabolism in mice fed a high-fat diet (HFD). Four-week-old C57/B6 male mice were fed a HFD for 12 weeks (HFD group) and the treatment group received oral BPS (300 mg/kg per day) for the same period. Then, glucose metabolism, histological changes, and gene expression of white adipose tissue (WAT) were examined. Body weight was increased, and glucose intolerance and insulin resistance were developed in the HFD group. Treatment with BPS improved glucose tolerance and insulin action without body weight change. Histological analysis of WAT showed an increase in the size of adipocyte and macrophage infiltration in the HFD group, which was attenuated by BPS treatment. BPS reduced HFD-induced expression of MCP1 and TNF-a in WAT. BPS also attenuated hepatic steatosis induced by the HFD. These results suggest that BPS improved glucose intolerance possibly through suppression of inflammatory cytokines in WAT. BPS may be beneficial for the treatment of obesity-associated glucose intolerance.

Original languageEnglish
Pages (from-to)285-291
Number of pages7
JournalJournal of Endocrinology
Volume213
Issue number3
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

beraprost
Obese Mice
High Fat Diet
Epoprostenol
Insulin Resistance
White Adipose Tissue
Glucose Intolerance
Cytokines
Adipocytes
Glucose
Tumor Necrosis Factor-alpha
Obesity
Synthetic Prostaglandins
Body Weight Changes
Chemokine CCL2

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. / Inoue, Eriko; Ichiki, Toshihiro; Takeda, Kotaro; Matsuura, Hirohide; Hashimoto, Toru; Ikeda, Jiro; Kamiharaguchi, Aya; Sunagawa, Kenji.

In: Journal of Endocrinology, Vol. 213, No. 3, 01.06.2012, p. 285-291.

Research output: Contribution to journalArticle

Inoue, E, Ichiki, T, Takeda, K, Matsuura, H, Hashimoto, T, Ikeda, J, Kamiharaguchi, A & Sunagawa, K 2012, 'Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice', Journal of Endocrinology, vol. 213, no. 3, pp. 285-291. https://doi.org/10.1530/JOE-12-0014
Inoue, Eriko ; Ichiki, Toshihiro ; Takeda, Kotaro ; Matsuura, Hirohide ; Hashimoto, Toru ; Ikeda, Jiro ; Kamiharaguchi, Aya ; Sunagawa, Kenji. / Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. In: Journal of Endocrinology. 2012 ; Vol. 213, No. 3. pp. 285-291.
@article{2095fb4488fc4ac0b1c4b5d6d2db54c3,
title = "Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice",
abstract = "Obesity induces hypertrophy of adipocyte resulting in production of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-α) and monocyte chemoattractant protein 1 (MCP1 (CCL2)). These cytokines play an important role in the development of insulin resistance. Beraprost sodium (BPS), a prostaglandin I2 analogue, is reported to attenuate inflammation. In this study, we examined the effect of BPS on glucose metabolism in mice fed a high-fat diet (HFD). Four-week-old C57/B6 male mice were fed a HFD for 12 weeks (HFD group) and the treatment group received oral BPS (300 mg/kg per day) for the same period. Then, glucose metabolism, histological changes, and gene expression of white adipose tissue (WAT) were examined. Body weight was increased, and glucose intolerance and insulin resistance were developed in the HFD group. Treatment with BPS improved glucose tolerance and insulin action without body weight change. Histological analysis of WAT showed an increase in the size of adipocyte and macrophage infiltration in the HFD group, which was attenuated by BPS treatment. BPS reduced HFD-induced expression of MCP1 and TNF-a in WAT. BPS also attenuated hepatic steatosis induced by the HFD. These results suggest that BPS improved glucose intolerance possibly through suppression of inflammatory cytokines in WAT. BPS may be beneficial for the treatment of obesity-associated glucose intolerance.",
author = "Eriko Inoue and Toshihiro Ichiki and Kotaro Takeda and Hirohide Matsuura and Toru Hashimoto and Jiro Ikeda and Aya Kamiharaguchi and Kenji Sunagawa",
year = "2012",
month = "6",
day = "1",
doi = "10.1530/JOE-12-0014",
language = "English",
volume = "213",
pages = "285--291",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice

AU - Inoue, Eriko

AU - Ichiki, Toshihiro

AU - Takeda, Kotaro

AU - Matsuura, Hirohide

AU - Hashimoto, Toru

AU - Ikeda, Jiro

AU - Kamiharaguchi, Aya

AU - Sunagawa, Kenji

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Obesity induces hypertrophy of adipocyte resulting in production of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-α) and monocyte chemoattractant protein 1 (MCP1 (CCL2)). These cytokines play an important role in the development of insulin resistance. Beraprost sodium (BPS), a prostaglandin I2 analogue, is reported to attenuate inflammation. In this study, we examined the effect of BPS on glucose metabolism in mice fed a high-fat diet (HFD). Four-week-old C57/B6 male mice were fed a HFD for 12 weeks (HFD group) and the treatment group received oral BPS (300 mg/kg per day) for the same period. Then, glucose metabolism, histological changes, and gene expression of white adipose tissue (WAT) were examined. Body weight was increased, and glucose intolerance and insulin resistance were developed in the HFD group. Treatment with BPS improved glucose tolerance and insulin action without body weight change. Histological analysis of WAT showed an increase in the size of adipocyte and macrophage infiltration in the HFD group, which was attenuated by BPS treatment. BPS reduced HFD-induced expression of MCP1 and TNF-a in WAT. BPS also attenuated hepatic steatosis induced by the HFD. These results suggest that BPS improved glucose intolerance possibly through suppression of inflammatory cytokines in WAT. BPS may be beneficial for the treatment of obesity-associated glucose intolerance.

AB - Obesity induces hypertrophy of adipocyte resulting in production of pro-inflammatory cytokines such as tumor necrosis factor-a (TNF-α) and monocyte chemoattractant protein 1 (MCP1 (CCL2)). These cytokines play an important role in the development of insulin resistance. Beraprost sodium (BPS), a prostaglandin I2 analogue, is reported to attenuate inflammation. In this study, we examined the effect of BPS on glucose metabolism in mice fed a high-fat diet (HFD). Four-week-old C57/B6 male mice were fed a HFD for 12 weeks (HFD group) and the treatment group received oral BPS (300 mg/kg per day) for the same period. Then, glucose metabolism, histological changes, and gene expression of white adipose tissue (WAT) were examined. Body weight was increased, and glucose intolerance and insulin resistance were developed in the HFD group. Treatment with BPS improved glucose tolerance and insulin action without body weight change. Histological analysis of WAT showed an increase in the size of adipocyte and macrophage infiltration in the HFD group, which was attenuated by BPS treatment. BPS reduced HFD-induced expression of MCP1 and TNF-a in WAT. BPS also attenuated hepatic steatosis induced by the HFD. These results suggest that BPS improved glucose intolerance possibly through suppression of inflammatory cytokines in WAT. BPS may be beneficial for the treatment of obesity-associated glucose intolerance.

UR - http://www.scopus.com/inward/record.url?scp=84864308908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864308908&partnerID=8YFLogxK

U2 - 10.1530/JOE-12-0014

DO - 10.1530/JOE-12-0014

M3 - Article

C2 - 22460613

AN - SCOPUS:84864308908

VL - 213

SP - 285

EP - 291

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -